Marshall Goldberg, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Goldberg M.; Dehydroepiandrosterone, Insulin-Like Growth Factor-I, and Prostate Cancer. Ann Intern Med. 1998;129:587-588. doi: 10.7326/0003-4819-129-7-199810010-00019
Download citation file:
Published: Ann Intern Med. 1998;129(7):587-588.
TO THE EDITOR:
In 1997, oral DHEA (dehydroepiandrosterone) was reportedly the fastest-selling product in health food stores. Millions of Americans are probably still taking medically unsupervised DHEA supplements in the belief that DHEA may have anti-aging properties. It may, but is it safe? On the basis of what's known of the relation between DHEA and insulin-like growth factor-I (IGF-I), it might not be.
In a recent issue of Science, Chan and coworkers  reported that high endogenous plasma IGF-I levels may represent a major risk factor for prostate cancer. In their series, men in the highest quartile of IGF-I levels had a relative risk for prostate cancer of 4.3 compared with men in the lowest IGF-I quartile; in men older than 60 years of age, the relative risk was 7.9. Along with growth hormone, DHEA is known to increase serum IGF-I levels. In a clinical study of 30 patients aged 40 to 70 years who were receiving 50 mg of DHEA daily for 3 months, Morales and colleagues  found that this hormone increased serum IGF-I levels in men from a mean of 151.3 ± 10.2 ng/mL to 180.1 ± 15.4 ng/mL and increased the bioavailability of IGF-I (ratio of IGF-I to IGF-binding protein type 1) by 52% ± 15.9%. In our study of 10 men aged 50 to 68 years given 25 mg of micronized DHEA for 3 months, mean IGF-I levels increased from 175 ± 11.8 ng/mL to 247 ± 16.2 ng/mL. Neither serum testosterone nor prostate-specific antigen levels changed significantly in any participant during this period.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only